Risk Factors Update Summary
- Future disease outbreaks could materially affect business, financials, and prospects, impacting operating results.
- Revenue sources shifted, with 2023 revenue: 75% from one source, 25% from others, compared to 63% and 37% in 2022.
- Net loss of $19 million in 2023 compared to net income of $30 million in 2022.
- Investment in new and pre-owned medical equipment to range from $80 million to $90 million.
- Increase in direct medical equipment purchases from ten manufacturers accounting for 65% in 2023, up from 55% in 2022.
- Weaknesses in controls over financial reporting identified, including insufficient resources and expertise.
- Number of outstanding shares increased from 133 million in February 2023 to 135 million in February 2024.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1749704&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.